{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:12:39Z","timestamp":1792552359592,"version":"4.5.0"},"reference-count":222,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82172716"],"award-info":[{"award-number":["82172716"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-small cell lung cancer (NSCLC) is characterized by several molecular alterations that contribute to its development and progression. These alterations include the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), human epidermal growth factor receptor 2 (HER2), and mesenchymal\u2013epithelial transition factor (c-MET). Among these, the hepatocyte growth factor (HGF)\/c-MET signaling pathway plays a crucial role in NSCLC. In spite of this, the involvement of the HGF\/c-MET signaling axis in remodeling the tumor microenvironment (TME) remains relatively unexplored. This review explores the biological functions of the HGF\/c-MET signaling pathway in both normal and cancerous cells, examining its multifaceted roles in the NSCLC tumor microenvironment, including tumor cell proliferation, migration and invasion, angiogenesis, and immune evasion. Furthermore, we summarize the current progress and clinical applications of MET-targeted therapies in NSCLC and discuss future research directions, such as the development of novel MET inhibitors and the potential of combination immunotherapy.<\/jats:p>","DOI":"10.3390\/ijms25169101","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:16:24Z","timestamp":1724649384000},"page":"9101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Unveiling the Role of HGF\/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4790-2439","authenticated-orcid":false,"given":"Shuxi","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangtian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelin","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: A heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Hunter","year":"2001","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.2012.43.9422","article-title":"MET as a possible target for non-small-cell lung cancer","volume":"31","author":"Sadiq","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","article-title":"Targeted therapy for head and neck cancer: Signaling pathways and clinical studies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_6","first-page":"419","article-title":"MET alterations in NSCLC-Current Perspectives and Future Challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2019.37.15_suppl.9004","article-title":"Capmatinib (INC280) in MET\u0394ex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study","volume":"37","author":"Wolf","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): A multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_9","first-page":"741","article-title":"Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations","volume":"15","author":"Jamme","year":"2020","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1158\/1078-0432.CCR-20-2861","article-title":"MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance","volume":"27","author":"Guo","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1158\/1078-0432.CCR-16-3273","article-title":"Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.7150\/ijbs.67892","article-title":"Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma","volume":"18","author":"Liang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-017-0712-x","article-title":"The biology of Hepatocellular carcinoma: Implications for genomic and immune therapies","volume":"16","author":"Khemlina","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Moreno, V.M., and Baeza, A. (2022). Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040784"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-022-01503-1","article-title":"Molecular mechanism(s) of regulation(s) of c-MET\/HGF signaling in head and neck cancer","volume":"21","author":"Raj","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1758835919855238","DOI":"10.1177\/1758835919855238","article-title":"Targeting the SLIT\/ROBO pathway in tumor progression: Molecular mechanisms and therapeutic perspectives","volume":"11","author":"Jiang","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-022-00922-2","article-title":"Colorectal liver metastasis: Molecular mechanism and interventional therapy","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0202-2","article-title":"Beyond EGFR inhibition: Multilateral combat strategies to stop the progression of head and neck cancer","volume":"51","author":"Byeon","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sagi, Z., and Hieronymus, T. (2018). The Impact of the Epithelial-Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor\/Met on Skin Immunity by Modulating Langerhans Cell Migration. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00517"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/ijms14010888","article-title":"HGF-MET cascade, a key target for inhibiting cancer metastasis: The impact of NK4 discovery on cancer biology and therapeutics","volume":"14","author":"Mizuno","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/BST20200394","article-title":"State of the structure address on MET receptor activation by HGF","volume":"49","author":"Linossi","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3390\/cancers5041601","article-title":"Role of met axis in head and neck cancer","volume":"5","author":"Xu","year":"2013","journal-title":"Cancers"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0092-8674(94)90318-2","article-title":"A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor\/scatter factor receptor family","volume":"77","author":"Ponzetto","year":"1994","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/aps.2010.90","article-title":"Hepatocyte growth factor in lung repair and pulmonary fibrosis","volume":"32","author":"Panganiban","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/atm.2016.12.78","article-title":"Effective implementation of novel MET pharmacodynamic assays in translational studies","volume":"5","author":"Srivastava","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wang, H., Rao, B., Lou, J., Li, J., Liu, Z., Li, A., Cui, G., Ren, Z., and Yu, Z. (2020). The Function of the HGF\/c-Met Axis in Hepatocellular Carcinoma. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00055"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(95)90404-2","article-title":"Dimerization of cell surface receptors in signal transduction","volume":"80","author":"Heldin","year":"1995","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/bjc.2011.322","article-title":"Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification","volume":"105","author":"Tanizaki","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/0008-5472.CAN-10-2100","article-title":"Ron kinase transphosphorylation sustains MET oncogene addiction","volume":"71","author":"Benvenuti","year":"2011","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4161\/cbt.5.9.3315","article-title":"New tools for dissecting RON receptor tyrosine kinase oncogenic signaling","volume":"5","author":"Kissil","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15397","DOI":"10.1074\/jbc.RA118.003063","article-title":"HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion","volume":"293","author":"Li","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1038\/onc.2011.84","article-title":"HGF-independent potentiation of EGFR action by c-Met","volume":"30","author":"Dulak","year":"2011","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"28970","DOI":"10.1074\/jbc.M402508200","article-title":"Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells","volume":"279","author":"Fischer","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7150\/jca.12663","article-title":"Understanding and Targeting MET Signaling in Solid Tumors\u2014Are We There Yet?","volume":"7","author":"Ariyawutyakorn","year":"2016","journal-title":"J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood-2015-07-658823","article-title":"Targeting HGF\/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma","volume":"126","author":"Dai","year":"2015","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/gcc.20604","article-title":"Expression and mutational analysis of MET in human solid cancers","volume":"47","author":"Ma","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_39","first-page":"197","article-title":"High MET copy number and MET overexpression: Poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol. Histopathol."},{"key":"ref_40","first-page":"331","article-title":"c-MET\/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas","volume":"7","author":"Tsuta","year":"2012","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"(2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511, 543\u2013550.","DOI":"10.1038\/nature13385"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1101\/gr.145144.112","article-title":"The transcriptional landscape and mutational profile of lung adenocarcinoma","volume":"22","author":"Seo","year":"2012","journal-title":"Genome Res."},{"key":"ref_45","first-page":"5","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_47","first-page":"1493","article-title":"Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","article-title":"Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer\u2014A systematic review and meta-analysis","volume":"123","author":"Vuong","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-021-01138-7","article-title":"Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer","volume":"14","author":"Drusbosky","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2016.34.15_suppl.108","article-title":"Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)","volume":"34","author":"Drilon","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_53","first-page":"e113","article-title":"MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor","volume":"10","author":"Lee","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_54","first-page":"e29","article-title":"MET Mutation Associated with Responsiveness to Crizotinib","volume":"10","author":"Waqar","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_55","first-page":"e33","article-title":"MET-Mutated NSCLC with Major Response to Crizotinib","volume":"10","author":"Mendenhall","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.cllc.2015.01.009","article-title":"Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation","volume":"16","author":"Jenkins","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2022.10.030","article-title":"Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study","volume":"183","author":"Wolf","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e2200674","DOI":"10.1200\/PO.22.00674","article-title":"Skipping or Not Skipping? That\u2019s the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non\u2013Small-Cell Lung Cancer","volume":"7","author":"Rolfo","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jtho.2018.12.020","article-title":"DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer","volume":"14","author":"Davies","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2021.08.008","article-title":"Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer","volume":"161","author":"Moore","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_61","first-page":"1293","article-title":"Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2015.10.028","article-title":"Responses to the multitargeted MET\/ALK\/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation","volume":"90","author":"Jorge","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): An open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12967-023-03999-7","article-title":"Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer","volume":"21","author":"Sun","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1038\/ncomms8174","article-title":"Activating MET kinase rearrangements in melanoma and Spitz tumours","volume":"6","author":"Yeh","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm.2819","article-title":"Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia","volume":"18","author":"Kentsis","year":"2012","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI0215418","article-title":"Dysregulation of Met receptor tyrosine kinase activity in invasive tumors","volume":"109","author":"Zbar","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17588359221144108","DOI":"10.1177\/17588359221144108","article-title":"Clinically relevant fusion oncogenes: Detection and practical implications","volume":"14","author":"Sorokin","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/gcc.23022","article-title":"Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications","volume":"61","author":"Kazdal","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.semcancer.2019.12.014","article-title":"Somatic copy number aberrations in metastatic patients: The promise of liquid biopsies","volume":"60","author":"Baldacchino","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102022","DOI":"10.1016\/j.ctrv.2020.102022","article-title":"The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping","volume":"87","author":"Salgia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Casado","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.canlet.2014.06.010","article-title":"MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET","volume":"351","author":"Zhou","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1111\/jcmm.13629","article-title":"miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT","volume":"22","author":"Jiao","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Ying, L., Zhu, Z., Xu, Z., He, T., Li, E., Guo, Z., Liu, F., Jiang, C., and Wang, Q. (2015). Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K\/Akt and GRP78 Signaling on a Microfluidic Platform. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129593"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: Interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-016-0541-3","article-title":"Wnt-signalling pathways and microRNAs network in carcinogenesis: Experimental and bioinformatics approaches","volume":"15","author":"Onyido","year":"2016","journal-title":"Mol. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12964-022-00840-4","article-title":"MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells","volume":"20","author":"Maharati","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1158\/0008-5472.CAN-12-3775","article-title":"EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis","volume":"73","author":"Breindel","year":"2013","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Morgan, R.D., Ferreras, C., Peset, I., Avizienyte, E., Renehan, A.G., Edmondson, R.J., Murphy, A.D., Nicum, S., Van Brussel, T., and Clamp, A.R. (2022). c-MET\/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: An exploratory biomarker study of the phase 3 ICON7 trial. BMC Med., 20.","DOI":"10.1186\/s12916-022-02270-y"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1038\/onc.2008.19","article-title":"Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members","volume":"27","author":"Wheeler","year":"2008","journal-title":"Oncogene"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1158\/0008-5472.CAN-06-1684","article-title":"Heterodimerization of insulin-like growth factor receptor\/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib","volume":"66","author":"Morgillo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/sj.bjc.6604937","article-title":"Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR\/Her2 inhibitor in non-small-cell lung cancer cells","volume":"100","author":"Agarwal","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-11-1171","article-title":"Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer","volume":"18","author":"Wang","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2353\/ajpath.2010.090863","article-title":"Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis","volume":"177","author":"Benedettini","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1021\/jm401427c","article-title":"Targeting receptor tyrosine kinase MET in cancer: Small molecule inhibitors and clinical progress","volume":"57","author":"Cui","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.21037\/tlcr-20-1113","article-title":"A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations","volume":"10","author":"Santarpia","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-19-0994","article-title":"Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial","volume":"25","author":"Landi","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1200\/JCO.2018.36.15_suppl.9062","article-title":"Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial","volume":"36","author":"Camidge","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","article-title":"Crizotinib in c-MET- or ROS1-positive NSCLC: Results of the AcS\u00e9 phase II trial","volume":"30","author":"Cozic","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Reckamp, K.L., Frankel, P.H., Ruel, N., Mack, P.C., Gitlitz, B.J., Li, T., Koczywas, M., Gadgeel, S.M., Cristea, M.C., and Belani, C.P. (2019). Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00132"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): A randomised, controlled, open-label, multicentre, phase 2 trial","volume":"17","author":"Neal","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: A multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"CT031","DOI":"10.1158\/1538-7445.AM2019-CT031","article-title":"Abstract CT031: Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations","volume":"79","author":"Lu","year":"2019","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1200\/JCO.2019.37.15_suppl.9005","article-title":"Phase II study of tepotinib in NSCLC patients with METex14 mutations","volume":"37","author":"Paik","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung","volume":"35","author":"Spigel","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_104","first-page":"80","article-title":"A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients","volume":"15","author":"Scagliotti","year":"2020","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/j.jtho.2019.08.1446","article-title":"P2. 01-103 Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations","volume":"14","author":"Dersarkissian","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S1085","DOI":"10.1016\/j.annonc.2022.07.1296","article-title":"1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study","volume":"33","author":"Cho","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2020.38.15_suppl.9510","article-title":"Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification\/exon 14 deletion (MET Amp\/Ex14\u2206)","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"TPS8593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8593","article-title":"A phase 1\/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC","volume":"40","author":"Drilon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1200\/JCO.2022.40.16_suppl.9016","article-title":"Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met\u2013overexpressing (OE) advanced non-small cell lung cancer (NSCLC)","volume":"40","author":"Camidge","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-17-0374","article-title":"Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms","volume":"16","author":"Grandal","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1200\/JCO.2018.78.7697","article-title":"First-in-human phase I, dose-escalation and-expansion study of telisotuzumab vedotin, an antibody\u2013drug conjugate targeting c-Met, in patients with advanced solid tumors","volume":"36","author":"Strickler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/1078-0432.CCR-21-0765","article-title":"Phase I study of 2-or 3-week dosing of telisotuzumab vedotin, an antibody\u2013drug conjugate targeting c-Met, monotherapy in patients with advanced non\u2013small cell lung carcinoma","volume":"27","author":"Camidge","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.22.00739","article-title":"Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein\u2013expressing non\u2013small-cell lung cancer","volume":"41","author":"Camidge","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_117","first-page":"100262","article-title":"A Phase 1b study of telisotuzumab vedotin in combination with nivolumab in patients with NSCLC","volume":"3","author":"Camidge","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The Tumor Microenvironment Innately Modulates Cancer Progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Bhide, S.A., and Nutting, C.M. (2010). Recent advances in radiotherapy. BMC Med., 8.","DOI":"10.1186\/1741-7015-8-25"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(21)00233-6","article-title":"Contemporary radiotherapy: Present and future","volume":"398","author":"Chandra","year":"2021","journal-title":"Lancet"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijrobp.2022.12.029","article-title":"Cancer-Associated Fibroblasts Promote Radioresistance of Breast Cancer Cells via the HGF\/c-Met Signaling Pathway","volume":"116","author":"Wang","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1182\/blood-2002-06-1731","article-title":"HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro","volume":"101","author":"Ding","year":"2003","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ccr.2004.05.032","article-title":"Targeting the tumor and its microenvironment by a dual-function decoy Met receptor","volume":"6","author":"Michieli","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-09-2448","article-title":"MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis","volume":"70","author":"Cha","year":"2010","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2009.23.5556","article-title":"Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer","volume":"27","author":"Roy","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.tips.2009.09.004","article-title":"Tumor and stromal pathways mediating refractoriness\/resistance to anti-angiogenic therapies","volume":"30","author":"Crawford","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-16-3216","article-title":"The HGF\/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer","volume":"23","author":"Cascone","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13046-022-02254-z","article-title":"FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner","volume":"41","author":"Huang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Boschert, V., Klenk, N., Abt, A., Janaki Raman, S., Fischer, M., Brands, R.C., Seher, A., Linz, C., M\u00fcller-Richter, U.D.A., and Bischler, T. (2020). The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020471"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1158\/1078-0432.CCR-15-0375","article-title":"Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer","volume":"21","author":"Iommelli","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12931-017-0604-z","article-title":"Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression","volume":"18","author":"Kanaji","year":"2017","journal-title":"Respir. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13543784.2020.1699532","article-title":"MET inhibitors in cancer: Pitfalls and challenges","volume":"29","author":"Oliveres","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yexcr.2018.07.041","article-title":"Paracrine HGF\/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP\/HIF-1\u03b1","volume":"371","author":"Yan","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cyto.2015.12.013","article-title":"The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions","volume":"82","author":"Ilangumaran","year":"2016","journal-title":"Cytokine"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12935-021-02051-2","article-title":"Molecular mechanism study of HGF\/c-MET pathway activation and immune regulation for a tumor diagnosis model","volume":"21","author":"Shen","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.mcn.2004.07.007","article-title":"HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms","volume":"27","author":"Thompson","year":"2004","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000143052.45956.71","article-title":"Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: Induction of tolerance and prevention of cardiac allograft vasculopathy","volume":"110","author":"Yamaura","year":"2004","journal-title":"Circulation"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","article-title":"Fates of CD8+ T cells in Tumor Microenvironment","volume":"17","author":"Maimela","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41577-018-0009-3","article-title":"An early history of T cell-mediated cytotoxicity","volume":"18","author":"Golstein","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1158\/1078-0432.CCR-03-0640","article-title":"Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes","volume":"10","author":"Schag","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e976077","DOI":"10.4161\/2162402X.2014.976077","article-title":"c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK\/T cell lymphoma","volume":"4","author":"Kumai","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15252\/embr.201744075","article-title":"Identification of a novel population of highly cytotoxic c-Met-expressing CD8(+) T lymphocytes","volume":"18","author":"Benkhoucha","year":"2017","journal-title":"EMBO Rep."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Benkhoucha, M., Tran, N.L., Senoner, I., Breville, G., Fritah, H., Migliorini, D., Dutoit, V., and Lalive, P.H. (2023). c-Met(+) Cytotoxic T Lymphocytes Exhibit Enhanced Cytotoxicity in Mice and Humans In Vitro Tumor Models. Biomedicines, 11.","DOI":"10.20944\/preprints202310.0583.v1"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41420-023-01313-4","article-title":"Hepatocyte growth factor-mediated apoptosis mechanisms of cytotoxic CD8(+) T cells in normal and cirrhotic livers","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1742-2094-10-154","article-title":"The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity","volume":"10","author":"Benkhoucha","year":"2013","journal-title":"J. Neuroinflamm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","article-title":"Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood.V99.8.2997","article-title":"Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils","volume":"99","author":"Grenier","year":"2002","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e1219828","DOI":"10.1080\/2162402X.2016.1219828","article-title":"Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma","volume":"5","author":"He","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_157","first-page":"1405","article-title":"Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: Role in tumor progression and death","volume":"63","author":"Wislez","year":"2003","journal-title":"Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e2312855121","DOI":"10.1073\/pnas.2312855121","article-title":"Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression","volume":"121","author":"Jing","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nature14407","article-title":"MET is required for the recruitment of anti-tumoural neutrophils","volume":"522","author":"Finisguerra","year":"2015","journal-title":"Nature"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Liu, Y., Smith, M.R., Wang, Y., D\u2019Agostino, R., Ruiz, J., Lycan, T., Kucera, G.L., Miller, L.D., Li, W., and Chan, M.D. (2023). c-Met Mediated Cytokine Network Promotes Brain Metastasis of Breast Cancer by Remodeling Neutrophil Activities. Cancers, 15.","DOI":"10.3390\/cancers15092626"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-023-01748-4","article-title":"Cross-talk between cancer stem cells and immune cells: Potential therapeutic targets in the tumor immune microenvironment","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4049\/jimmunol.166.2.1241","article-title":"Hepatocyte growth factor is a regulator of monocyte-macrophage function","volume":"166","author":"Galimi","year":"2001","journal-title":"J. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1189\/jlb.3A0513-242R","article-title":"Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1\/2","volume":"96","author":"Chen","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/ijc.31562","article-title":"Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors","volume":"143","author":"Krug","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Choi, W., Lee, J., Lee, J., Lee, S.H., and Kim, S. (2019). Hepatocyte Growth Factor Regulates Macrophage Transition to the M2 Phenotype and Promotes Murine Skeletal Muscle Regeneration. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.00914"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41416-019-0482-x","article-title":"M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma","volume":"121","author":"Dong","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e002451","DOI":"10.1136\/jitc-2021-002451","article-title":"MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13287-019-1488-2","article-title":"Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury","volume":"10","author":"Lu","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.4049\/jimmunol.175.7.4745","article-title":"A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function","volume":"175","author":"Okunishi","year":"2005","journal-title":"J. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.biocel.2011.04.006","article-title":"Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking I\u03baB kinase activity","volume":"43","author":"Singhal","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"32054","DOI":"10.1074\/jbc.M111.271247","article-title":"A novel role for Bruton\u2019s tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells","volume":"286","author":"Singhal","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood-2005-08-3141","article-title":"Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low\/neg accessory cells with dendritic-cell features","volume":"108","author":"Rutella","year":"2006","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/eji.1830250722","article-title":"Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10","volume":"25","author":"Ludewig","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E","article-title":"Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules","volume":"71","author":"Yue","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1189\/jlb.0311177","article-title":"Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice","volume":"91","author":"Youn","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.stemcr.2013.06.006","article-title":"Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor\/c-met and STAT3","volume":"1","author":"Yen","year":"2013","journal-title":"Stem Cell Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"119626","DOI":"10.1016\/j.lfs.2021.119626","article-title":"MicroRNA-150 inhibits myeloid-derived suppressor cells proliferation and function through negative regulation of ARG-1 in sepsis","volume":"278","author":"Liu","year":"2021","journal-title":"Life Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13287-020-01612-y","article-title":"Mesenchymal stem cells regulate the Th17\/Treg cell balance partly through hepatocyte growth factor in vitro","volume":"11","author":"Chen","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1073\/pnas.0912437107","article-title":"Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells","volume":"107","author":"Benkhoucha","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1479-5876-10-247","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma","volume":"10","author":"Bonanno","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/s41423-020-0487-7","article-title":"PD-L1(+) exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity","volume":"18","author":"Sun","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","article-title":"MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer","volume":"24","author":"Saigi","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Ahn, H.K., Kim, S., Kwon, D., Koh, J., Kim, Y.A., Kim, K., Chung, D.H., and Jeon, Y.K. (2019). MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174287"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","article-title":"EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Minne, R.L., Luo, N.Y., Traynor, A.M., Huang, M., DeTullio, L., Godden, J., Stoppler, M., Kimple, R.J., and Baschnagel, A.M. (2024). Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer. Clin. Lung Cancer, in press.","DOI":"10.1016\/j.cllc.2024.05.001"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/cbin.11697","article-title":"HGF\/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma","volume":"45","author":"Zhang","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00109-022-02179-2","article-title":"c-Met up-regulates the expression of PD-L1 through MAPK\/NF-\u03baBp65 pathway","volume":"100","author":"Xu","year":"2022","journal-title":"J. Mol. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1074\/jbc.M114.612689","article-title":"Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression","volume":"290","author":"Balan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13046-021-02055-w","article-title":"Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy","volume":"40","author":"Li","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/0008-5472.CAN-22-0770","article-title":"MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer","volume":"82","author":"Yoshida","year":"2022","journal-title":"Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-10-4246","article-title":"CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis","volume":"71","author":"Stagg","year":"2011","journal-title":"Cancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Vigano, S., Alatzoglou, D., Irving, M., M\u00e9n\u00e9trier-Caux, C., Caux, C., Romero, P., and Coukos, G. (2019). Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00925"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41423-018-0021-3","article-title":"Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells","volume":"16","author":"Zhang","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_198","first-page":"564","article-title":"Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma","volume":"10","author":"Sun","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","article-title":"MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1","volume":"156","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2020.01.005","article-title":"Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer","volume":"141","author":"Yoshimura","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Iwai, Y., Hamanishi, J., Chamoto, K., and Honjo, T. (2017). Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci., 24.","DOI":"10.1186\/s12929-017-0329-9"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/2159-8290.CD-20-1500","article-title":"MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2021.10.025","article-title":"Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma","volume":"81","author":"Lindner","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"29067","DOI":"10.18632\/oncotarget.16173","article-title":"A novel bispecific c-MET\/PD-1 antibody with therapeutic potential in solid cancer","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Li, J.F., Niu, Y.Y., Xing, Y.L., and Liu, F. (2019). A novel bispecific c-MET\/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer. Biosci. Rep., 39.","DOI":"10.1042\/BSR20171278"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.2147\/DDDT.S254117","article-title":"Suppression of c-Met-Overexpressing Tumors by a Novel c-Met\/CD3 Bispecific Antibody","volume":"14","author":"Huang","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10637-018-0689-3","article-title":"A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer","volume":"37","author":"Hou","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.drudis.2018.02.012","article-title":"Approved CAR T cell therapies: ICE bucket challenges on glaring safety risks and long-term impacts","volume":"23","author":"Zheng","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"9216","DOI":"10.1080\/21655979.2022.2058149","article-title":"c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549","volume":"13","author":"Min","year":"2022","journal-title":"Bioengineered"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e1363137","DOI":"10.1080\/2162402X.2017.1363137","article-title":"CAR T-cell immunotherapy of MET-expressing malignant mesothelioma","volume":"6","author":"Thayaparan","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10637-020-00978-3","article-title":"Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors","volume":"39","author":"Yuan","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Jiang, W., Li, T., Guo, J., Wang, J., Jia, L., Shi, X., Yang, T., Jiao, R., Wei, X., and Feng, Z. (2021). Bispecific c-Met\/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.546586"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Kang, C.H., Kim, Y., Lee, D.Y., Choi, S.U., Lee, H.K., and Park, C.H. (2021). c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer. Cancers, 13.","DOI":"10.3390\/cancers13225738"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/cas.14835","article-title":"Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model","volume":"112","author":"Mori","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jcyt.2023.06.004","article-title":"c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma","volume":"25","author":"Huo","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1901434","DOI":"10.1080\/2162402X.2021.1901434","article-title":"Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13046-022-02479-y","article-title":"Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy","volume":"41","author":"Chiriaco","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"106656","DOI":"10.1016\/j.phrs.2023.106656","article-title":"Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma","volume":"188","author":"Peng","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"112273","DOI":"10.1016\/j.intimp.2024.112273","article-title":"Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells","volume":"136","author":"Chiawpanit","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_222","first-page":"2823","article-title":"Development of c-MET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells","volume":"20","author":"Liu","year":"2019","journal-title":"Mol. Med. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/9101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:41:00Z","timestamp":1760110860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/9101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":222,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25169101"],"URL":"https:\/\/doi.org\/10.3390\/ijms25169101","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}